Drugs without bio-equivalency proof to exit from markets.

Published: 2001-10-11 07:00:00

Updated: 2001-10-11 07:00:00

Effective from Nov. this year under the new MOHW provision, the NHI reimbursement plan will not be applicable for the drugs that were not proven with their bio-equivalency. This may give a serious impact to the drug industry who failed the test as the technical environment was too premature to co...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK